Cardiol Therapeutics Inc 40-F/A for FY2021
Cardiol Therapeutics Inc. (CRDL)
About this 40-F/A
Cardiol Therapeutics Inc filed this 40-F/A on April 20, 2022, covering the fiscal year ended December 31, 2021 (FY2021).
Headline figures
Fiscal year ended December 31, 2021, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- 78.76K CAD
- Net loss
- 31.64M CAD
- compared with a net loss of 20.64M CAD a year earlier
- Diluted EPS
- -0.73 CAD
- compared with -0.69 CAD a year earlier
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form
(Amendment No. 1)
(Check One)
OR
For the fiscal year ended: | Commission File Number: |
(Exact name of Registrant as specified in its charter)
Not Applicable
(Translation of Registrant’s name into English (if applicable))
(Province or other jurisdiction of incorporation or organization)
(Primary Standard Industrial Classification Code Number (if applicable))
Not Applicable
(I.R.S. Employer Identification Number (if applicable))
(
(Address and telephone number of Registrant’s principal executive offices)
(
(Name, address (including zip code) and telephone number (including area code) of agent for service in the United States)
Securities registered or to be registered pursuant to Section 12(b) of the Act:
Title of each class | Ticker Symbol(s) | Name of each exchange |
The |
Securities registered or to be registered pursuant to Section 12(g) of the Act:
None
(Title of Class)
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:
None
(Title of Class)
For annual reports, indicate by check mark the information filed with this Form:
Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report:
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
☒ NO ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
☒ NO ☐
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.
Emerging growth company
If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
EXPLANATORY NOTE
Cardiol Therapeutics Inc., an Ontario corporation (the “Registrant”), is filing this Amendment No. 1 (the “Amendment”) to Form 40-F (the “Form 40-F/A”) for the year ended December 31, 2021, to furnish exhibits 101 and 104, which provide certain items from the Registrant's Form 40-F formatted as Inline eXtensible Business Reporting Language (“XBRL”). In accordance with the policy of the Securities and Exchange Commission (the “Commission”) stated in Release No. 33-9002, the Registrant is filing this Form 40F/A within the 30-day period available to first time XBRL filers following the filing of the Registrant's Form 40-F, as filed with the Commission on March 24, 2022 (the “Original Filing”).
No other changes have been made to the Original Filing other than the furnishing of the exhibits described above, and no changes have been made to the financial statements previously filed as Exhibit 99.2 to the Original Filing. This Form 40-F/A does not reflect subsequent events occurring after the date of the Original Filing, or modify or update in any way disclosures made in the Original Filing. Accordingly, this Form 40-F/A should be read in conjunction with the Original Filing.
EXHIBIT INDEX
Exhibit No. |
| Title of Exhibit |
99.1* | | Annual Information Form of the Registrant for the year ended December 31, 2021 |
| |
|
99.2 | | |
| |
|
99.3* | | Management Discussion and Analysis of the Registrant for the year ended December 31, 2021 |
| |
|
99.4* | | |
| |
|
99.5* | | |
| |
|
99.6* | | |
| |
|
99.7* | | |
| |
|
99.8* | | Consent of Independent Registered Public Accounting Firm – BDO Canada LLP (PCAOB ID: |
| |
|
101 | | Interactive Data File (formatted as Inline XBRL) |
| |
|
104 | | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
* | Previously filed. |
SIGNATURES
Pursuant to the requirements of the Exchange Act, the Registrant certifies that it meets all of the requirements for filing on Form 40-F and has duly caused this Amendment No. 1 to be signed on its behalf by the undersigned, thereunto duly authorized.
| Cardiol Therapeutics Inc. | |
|
|
|
| By: | /s/ Chris Waddick |
|
| Name: Chris Waddick |
|
| Title: Chief Financial Officer |
|
|
|
Date: April 20, 2022 |
|
|